Novo Nordisk

Novo Nordisk announced today that it plans to invest $1.2 billion (8.5 billion Danish kroner) in a new production facility in Odense, Denmark. The company said this marks the first time in this century that it breaks ground in Denmark by establishing a new production site. Novo Nordisk plans to include a state-of-the-art finished production…

Novo Nordisk announced that it plans to build a new factory in Køge, Denmark, to support the production of raw materials. The company’s Pharmatech business said it decided to build the factory in response to higher demand for raw materials for the production of medicines to fight chronic diseases. Novo Nordisk Pharmatech bought the 47,000-square-meter…

Novo Nordisk today announced plans to invest $4.1 billion to build a new manufacturing facility in North Carolina. The Denmark-based company will build a second fill and finishing manufacturing facility in Clayton, North Carolina, to grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases. Novo…

Novo Nordisk’s semaglutide achieved explosive sales in 2023. Ozempic alone generated $13,892 million in sales for the year. But now that Hims & Hers has revealed plans to sell compounded semaglutide to the masses, questions arise about how the Dutch pharma giant will respond. 2023 was a banner year for the firm with its diabetes…

Ginkgo Bioworks today announced it expanded its strategic partnership with Novo Nordisk to manufacture medicines for chronic diseases. Under the framework agreement, the partnership is slated to run over five years. Ginkgo Bioworks develops a platform for cell programming and biosecurity, while Novo Nordisk develops a series of medications for chronic conditions, including its Wegovy…

Over the past three months, the pharma sector has seen a string of investments in manufacturing facilities, especially in Europe. While the European economy lost momentum in 2023 owing to a high cost of living, weak external demand, and monetary tightening, the prospects for growth remain stronger with the EU GDP growth forecast to improve…

Novo Nordisk announced last week that it plans to invest approximately 16 billion Danish kroner in GLP-1 drug production. That equates to about $2.32 billion or €2.14 billion. The company plans to expand its Chartres, France, production site for its current and future product portfolio within serious chronic diseases. This investment significantly increases the capacity…

The Biden-Harris Administration has nominated 10 drugs for price negotiations directly with pharmaceutical giants after capping monthly insulin costs at $35. Americans have historically paid more for prescription drugs than most other major economies. In a fact sheet, the White House highlighted that seniors paid $3.4 billion in out-of-pocket costs for these drugs just last…

A pair of weight-loss drugs —  semaglutide and tirzapatide — could reshape the way we view and treat obesity, according to a Moody’s report dated May 18. The ratings firm notes that Novo Nordisk could benefit from a first-mover advantage in the obesity market as it now has two novel weight loss drugs on the…

The state of California has established a $50 million collaboration over a decade with the generic drug manufacturer Civica. The goal of the collaboration is to create affordable state-branded generic insulin. Qualified individuals may obtain a 10-mL vial of generic insulin for $30 or less. California plans to provide a pack containing five prefilled 3…